BRPI0412799A - imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura - Google Patents

imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura

Info

Publication number
BRPI0412799A
BRPI0412799A BRPI0412799-4A BRPI0412799A BRPI0412799A BR PI0412799 A BRPI0412799 A BR PI0412799A BR PI0412799 A BRPI0412799 A BR PI0412799A BR PI0412799 A BRPI0412799 A BR PI0412799A
Authority
BR
Brazil
Prior art keywords
inducing
patient
nucleic acid
response
polypeptide
Prior art date
Application number
BRPI0412799-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Annaliesa S Anderson
Kathrin Ute Jansen
Rosemarie Kelly
Loren D Schultz
Donna L Montgomery
William L Mcclements
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34107815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0412799(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0412799A publication Critical patent/BRPI0412799A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0412799-4A 2003-07-24 2004-07-22 imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura BRPI0412799A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48984003P 2003-07-24 2003-07-24
US52011503P 2003-11-14 2003-11-14
PCT/US2004/023523 WO2005009379A2 (en) 2003-07-24 2004-07-22 Polypeptides for inducing a protective immune response against staphylococcus aureus

Publications (1)

Publication Number Publication Date
BRPI0412799A true BRPI0412799A (pt) 2006-09-26

Family

ID=34107815

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412799-4A BRPI0412799A (pt) 2003-07-24 2004-07-22 imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura

Country Status (23)

Country Link
US (2) US20060177462A1 (enExample)
EP (1) EP1651166B8 (enExample)
JP (1) JP2007502101A (enExample)
KR (1) KR20060065643A (enExample)
AT (1) ATE457737T1 (enExample)
AU (1) AU2004258979B2 (enExample)
BR (1) BRPI0412799A (enExample)
CA (1) CA2532370A1 (enExample)
CY (1) CY1110028T1 (enExample)
DE (1) DE602004025579D1 (enExample)
DK (1) DK1651166T3 (enExample)
ES (1) ES2342778T3 (enExample)
HR (1) HRP20100240T1 (enExample)
IL (1) IL173253A0 (enExample)
IS (1) IS8213A (enExample)
MX (1) MXPA06000854A (enExample)
NO (1) NO20060898L (enExample)
NZ (2) NZ544542A (enExample)
PL (1) PL1651166T3 (enExample)
PT (1) PT1651166E (enExample)
RU (1) RU2337108C2 (enExample)
SI (1) SI1651166T1 (enExample)
WO (1) WO2005009379A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
CN1918176A (zh) * 2004-02-18 2007-02-21 默克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
WO2006059247A2 (en) * 2004-10-25 2006-06-08 The University Of Western Ontario VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
JP2009524428A (ja) * 2006-01-27 2009-07-02 メルク エンド カムパニー インコーポレーテッド スタヒロコッカス・アウレウスｏｒｆ０６５７ｎを標的とする抗原結合タンパク質
CN101610781A (zh) 2007-01-24 2009-12-23 默克公司 用于诱导针对表皮葡萄球菌的保护性免疫应答的多肽
ATE537839T1 (de) * 2007-05-04 2012-01-15 Martin Kroenke Impfstoff zum schutz gegen staphylococcus aureus auf der basis zellwandassoziierter proteine
KR20100021577A (ko) * 2007-05-31 2010-02-25 머크 앤드 캄파니 인코포레이티드 에스.아우레우스 ＯＲＦ0657ｎ을 표적화하는 항원 결합 단백질
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
EP2376111A4 (en) 2008-11-26 2013-01-09 Merck Sharp & Dohme POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
HRP20160274T1 (hr) 2009-04-03 2016-04-08 University Of Chicago Pripravci i metode vezane za varijante proteina a (spa)
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
PT2493498T (pt) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US20130004539A1 (en) * 2010-03-12 2013-01-03 Jeffrey Weiser Methods for preventing and treating staphylococcus aureus colonization, infection, and disease
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
EP2593133A4 (en) 2010-07-13 2014-11-26 Merck Sharp & Dohme STAPHYLOCOCCUS AUREUS SURFACE PROTEIN SA1789 AND PROTECTIVE VACCINE BASED ON IT
WO2012065034A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
SG11201400210RA (en) 2011-09-01 2014-03-28 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
WO2013066731A2 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2451 protein
ES2597228T3 (es) * 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
EP2872173A4 (en) 2012-07-10 2016-03-23 Merck Sharp & Dohme PROTECTIVE VACCINE BASED ON THE STAPHYLOCOCCUS AUREUS PROTEIN SA2493
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CA3139981A1 (en) 2019-05-14 2020-11-19 The University Of Chicago Methods and compositions comprising staphylococcus protein a (spa) variants
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
JP2003503015A (ja) * 1999-05-03 2003-01-28 メダレツクス・インコーポレーテツド スタフィロコッカス・アウレウスに対するヒト抗体
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP2339344A1 (en) * 2001-06-15 2011-06-29 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
JP4291152B2 (ja) * 2001-11-12 2009-07-08 ノボ ノルディスク アクティーゼルスカブ 金属イオンアフィニティークロマトグラフィーによるペプチドの精製
EP1455817B1 (en) * 2001-12-11 2008-12-31 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
AU2007281934B2 (en) * 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins

Also Published As

Publication number Publication date
DE602004025579D1 (de) 2010-04-01
PL1651166T3 (pl) 2010-08-31
EP1651166B8 (en) 2010-05-19
AU2004258979B2 (en) 2007-12-06
AU2004258979A1 (en) 2005-02-03
CA2532370A1 (en) 2005-02-03
HRP20100240T1 (hr) 2010-09-30
EP1651166B1 (en) 2010-02-17
NZ544542A (en) 2009-01-31
US20100247561A1 (en) 2010-09-30
WO2005009379A2 (en) 2005-02-03
NO20060898L (no) 2006-04-24
PT1651166E (pt) 2010-04-23
US20060177462A1 (en) 2006-08-10
SI1651166T1 (sl) 2010-06-30
RU2006105498A (ru) 2006-09-10
WO2005009379A3 (en) 2006-11-30
MXPA06000854A (es) 2006-03-30
IS8213A (is) 2005-12-30
KR20060065643A (ko) 2006-06-14
RU2337108C2 (ru) 2008-10-27
NZ570750A (en) 2009-12-24
CY1110028T1 (el) 2015-01-14
EP1651166A4 (en) 2008-03-05
IL173253A0 (en) 2006-06-11
JP2007502101A (ja) 2007-02-08
DK1651166T3 (da) 2010-05-31
ATE457737T1 (de) 2010-03-15
EP1651166A2 (en) 2006-05-03
ES2342778T3 (es) 2010-07-14

Similar Documents

Publication Publication Date Title
IL173253A0 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
DK1317537T3 (da) Sammensætninger og fremgangsmåder med G-CSF analoger
WO2005079315A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
BR0107703A (pt) Flavivìrus recombinantes e processos para uso dos mesmos
FI100056B (fi) Ihmisproapolipoproteiinin A-I ilmaiseminen
BR9712971A (pt) Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica
DE69637874D1 (de) C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2
RU2003103779A (ru) Экспрессионная система
DK0851926T3 (da) Varianter af humant rekombinant gamminterferon (rhu-IFN-gamma) med forøget termisk stabilitet
BR112022026248A2 (pt) Conjugados de citocinas
DE60323634D1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
PT1151103E (pt) Nac1 - um gene de plantas codificador de um factor de transcricao envolvido no desenvolvimento de cotiledones e raizes laterais
KR940021579A (ko) 골(骨)-관련 전사 조절인자형 단백질 및 이의 제조방법
WO2005086663A3 (en) Polypeptides for inducing a protective immune response against staphlococcus aureus
WO2006033918A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
TW200716166A (en) Lawsonia intracellularis immunological proteins
BRPI0309787E2 (pt) Polipeptídeo isolado, composição de vacina anti-carrapato de espécies múltiplas, molécula de cdna isolada, vetor de expressão, célula isolada, vacina anti-carrapato de espécie múltipla, e, método de induzir uma resposta imune em um mamífero contra a infestação de carrapato de espécie múltipla e seus patógenos associados
DK1005487T3 (da) Ydre 74 kD-membranprotein fra Moraxella catarrhalis
ATE452970T1 (de) N-desoxyribosyltransferase aus lactobacillus, entsprechende nukleinsäuren darauf und ihre verwendungen
ATE399794T1 (de) Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
BR0017015A (pt) Toxina estafilocócica modificada, gene codificante, vetor de expressão, célula e métodos de produção de polipeptìdeo, de separação e purificação da toxina e de, produção de vacina.
NO20055724L (no) Immunogene humane TNF alfa analoger med redusert cytotoksisiter og fremgangsmater for deres fremstilling
Houard et al. Cloning, expression and purification of recombinant cotton rat interferon-gamma
ATE305941T1 (de) Impfstoff
LT2002133A (en) Chaperons DnaK, DnaJ and GrpE from Meiothermus ruber having increased thermal stability and system and process for refolding proteins in vitro

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: ALTERADO DE: MERCK AND CO., INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]